Chapter 5. Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

  1. Nils Erik Gilhus MD, PhD Professor10,
  2. Michael P. Barnes MD, FRCP Professor of Neurological Rehabilitation Medical Director11 and
  3. Michael Brainin MD Professor12
  1. P. Soelberg Sørensen1,
  2. F. Deisenhammer2,
  3. P. Duda3,
  4. R. Hohlfeld4,
  5. K.-M. Myhr5,
  6. J. Palace6,
  7. C. Polman7,
  8. C. Pozzilli8 and
  9. C. Ross9

Published Online: 6 SEP 2010

DOI: 10.1002/9781444328394.ch5

European Handbook of Neurological Management, Second Edition, Volume 1, Second Edition

European Handbook of Neurological Management, Second Edition, Volume 1, Second Edition

How to Cite

Gilhus, N. E., Barnes, M. P. and Brainin, M. (2010) Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis, in European Handbook of Neurological Management, Second Edition, Volume 1, Second Edition, Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444328394.ch5

Author Information

  1. 10

    Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway

  2. 11

    University of Newcastle, Hunters Moor Neurorehabilitation Ltd, Newcastle upon Tyne, UK

  3. 12

    Department of Clinical Medicine and Prevention, and Center for Clinical Neurosciences, Donau-Universität Krems, Department of Neurology, Landesklinikum Donauregion Tulln Tulln, Austria

Author Information

  1. 1

    Copenhagen Danish Multiple Sclerosis Research Center, Copenhagen University Hospital, Rigshospitalet, Denmark

  2. 2

    University of Innsbruck, Austria

  3. 3

    University Hospitals, Basel, Switzerland

  4. 4

    Institute for Clinical Neuroimmunology, University of Munich, Klinikum Grosshadern, Germany

  5. 5

    Haukeland University Hospital, Bergen, Norway

  6. 6

    Multiple Sclerosis Group, Radcliffe Infirmary, Oxford, UK

  7. 7

    VU University Medical Center, Amsterdam, The Netherlands

  8. 8

    II Faculty of Medicine, University ‘La Sapienza’, Rome, Italy

  9. 9

    Institute for Inflammation Research, Copenhagen University Hospital, Rigshospitalet, Denmark

Publication History

  1. Published Online: 6 SEP 2010
  2. Published Print: 15 OCT 2010

ISBN Information

Print ISBN: 9781405185332

Online ISBN: 9781444328394

SEARCH

Keywords:

  • use of anti-interferon beta antibody measurements - in multiple sclerosis;
  • interferon (IFN) β, first-line therapy for relapsing–remitting multiple sclerosis (MS);
  • binding antibodies (BABs) and neutralizing antibodies (NABs) - occurring during treatment with recombinant IFN β products;
  • dynamics of NABs;
  • frequency of NAB - positive patients in initial pivotal placebo-controlled trials;
  • immunogenicity of recombinant IFN β - to be most influenced by formulation itself;
  • measurements of binding and neutralizing antibodies;
  • advantage of affinity chromatography assay (ACA) and radio-immunoprecipitation assay (RIPA), that antigen is in solution;
  • methods used for BAB detection - ELISA method, Western Blot (WB) method and radio-immunoprecipitation (RIPA) or affinity chromatography (ACA) assays;
  • plasmapheresis and immunoglobulins (IgG) - possible procedures to diminish NAB generation

Summary

This chapter contains sections titled:

  • Background and objectives

  • Search strategy and consensus

  • Immunogenicity

  • Measurements of binding and neutralizing antibodies

  • Prevention and treatment of NABs

  • References